A phase III study on CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia found statistically significant and clinically meaningful improvement in overall survival compared to placebo.
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
